Lisa Barrett

Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics

A. Osinusi, Eric G. Meissner, Y.-J. Lee et al. · JAMA · 2013 · 287 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis

Darrell H. S. Tan, Mark Hull, Deborah Yoong et al. · Canadian Medical Association Journal · 2017 · 227 citations · Full text

Public Health, Infectious Disease Control, Preventive Medicine +13

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study

Anita Kohli, A. Osinusi, Zayani Sims et al. · The Lancet · 2015 · 151 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study

Alison D. Marshall, Sahar Saeed, Lisa Barrett et al. · CMAJ Open · 2016 · 85 citations · Full text

Pharmacy, Health Policy, Infectious Diseases +17

Investigating the Sensitivity of Nasal or Throat Swabs: Combination of Both Swabs Increases the Sensitivity of SARS-CoV-2 Rapid Antigen Tests

Barbara Goodall, Jason J. LeBlanc, Todd F. Hatchette et al. · Microbiology Spectrum · 2022 · 39 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +13